Deferred Tax Assets, Valuation Allowance in USD of Trevi Therapeutics, Inc. from Q4 2018 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Trevi Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and change rate from Q4 2018 to Q4 2024.
  • Trevi Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $82.4M, a 18.6% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Trevi Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed
Q4 2024 $82.4M +$12.9M +18.6% 31 Dec 2024 10-K 18 Mar 2025
Q4 2023 $69.5M +$8.43M +13.8% 31 Dec 2023 10-K 18 Mar 2025
Q4 2022 $61.1M +$8.38M +15.9% 31 Dec 2022 10-K 20 Mar 2024
Q4 2021 $52.7M +$9.87M +23% 31 Dec 2021 10-K 16 Mar 2023
Q4 2020 $42.8M +$9.53M +28.6% 31 Dec 2020 10-K 17 Mar 2022
Q4 2019 $33.3M +$7.36M +28.4% 31 Dec 2019 10-K 25 Mar 2021
Q4 2018 $25.9M 31 Dec 2018 10-K 16 Mar 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.